Health Trials

Clinical trials

7

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

The main purpose of this study is to evaluate the efficacy of MY008211A in adult patients with PNH, showing signs of active hemolysis.

Participants needed: 40
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Wuhan Createrna Science and Technology Co., LtdUpdated: Jul 29, 2025
Eligibility criteria

Male and female participants ≥ 18 years of age and BMI ≥ 18.0 kg/m2 with a diagn... [+3]

Patients with reticulocytes <100x10^9/L; platelets <30x10^9/L; neutrophils <0.5x... [+6]

Read more
Status: Recruiting

Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

The main purpose of this study is to evaluate the efficacy of MY008211A compared to eculizumab in PNH patients.

Participants needed: 66
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Wuhan Createrna Science and Technology Co., LtdUpdated: May 9, 2025Locations: 2
Eligibility criteria

Male and female participants ≥ 18 years of age and BMI ≥ 18.0 kg/m2 with a diagn... [+3]

Patients with reticulocytes <100x10^9/L; platelets <30x10^9/L; neutrophils <0.5x... [+5]

Read more
Status: Recruiting

Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

The main purpose of this study is to evaluate the efficacy of MY008211A in PNH patients with residual anemia despite treatment with anti-C5 antibody.

Participants needed: 20
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Wuhan Createrna Science and Technology Co., LtdUpdated: May 9, 2025Locations: 1
Eligibility criteria

Male and female participants ≥ 18 years of age and BMI ≥ 18.0 kg/m2 with a diagn... [+4]

Patients with reticulocytes <100x10^9/L; platelets <30x10^9/L; neutrophils <0.5x... [+5]

Read more
Status: Recruiting

Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria

This is a multicenter, single-arm, open-label study to characterize long-term safety and tolerability of MY008211A tablets and to provide access to MY008211A tablets to patients with PNH who have completed Phase 2 or 3 studies with MY008211A tablets.

Participants needed: 120
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Wuhan Createrna Science and Technology Co., LtdUpdated: Apr 18, 2025Locations: 1
Eligibility criteria

Patients who have previously received and completed MY008211A study treatment, a... [+1]

History of recurrent invasive infections caused by encapsulated organisms, e.g.... [+2]

Read more
Status: Not yet recruiting

QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril/valsartan 200mg in patients with moderate to severe essential hypertension.

Participants needed: 810
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Wuhan Createrna Science and Technology Co., LtdUpdated: Dec 6, 2024Locations: 1
Eligibility criteria

Subjects who can understand and are willing to complying with protocol requireme... [+3]

History or evidence of a secondary form of hypertension. [+23]

Read more
Participants needed: 72
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Wuhan Createrna Science and Technology Co., LtdUpdated: Nov 18, 2024Locations: 1
Eligibility criteria

Males or females ≥ 18 and ≤ 75 years of age at Screening. [+7]

Systolic blood pressure >130 mm Hg or diastolic blood pressure >80 mm Hg. [+10]

Read more
Status: Not yet recruiting

To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects

A Concentration-QT Interval Correction (C-QTc) study of MY008211A Tablets in Healthy Subjects

Participants needed: 16
Trial details
Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Wuhan Createrna Science and Technology Co., LtdUpdated: Aug 9, 2024Locations: 1
Eligibility criteria

Volunteers must be fully informed of this study and the content, process of the... [+3]

The investigator judges that there are other disease or medical conditions that... [+26]

Read more